| Title | Long-acting erythromycins: assessing their role in treating outpatient odontogenic infections. | | Author(s) | Alexander RE, Grogan DM | | Institution | Department of Oral & Maxillofacial Surgery, Baylor College of Dentistry, Texas A&M University Health Science Center, Dallas, TX, USA. | | Source | Tex Dent J 2009 Apr; 126(4):326-33. | | Abstract | Erythromycins have been part of our armamentarium against selected bacterial infections since they were discovered in 1952 and approved by the Food and Drug Administration (FDA) in 1964. In 1991, two newer, long-acting erythromycin analogues, azythromycin (brand name: Zithromax) and clarithromycin (brand name: Biaxin) were approved by the FDA. They were joined a few years later by a third long-acting form, dirithromycin (brand name: Dynabac). | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19472551 |
|
